79 related articles for article (PubMed ID: 26977008)
1. Targeting of Receptor Activator of Nuclear Kappa B (RANK) in PC-3 Cells Increases Cell Proliferation and Matrix Adhesion In Vitro.
Owen S; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2016 Mar; 36(3):1127-34. PubMed ID: 26977008
[TBL] [Abstract][Full Text] [Related]
2. Importance of osteoprotegrin and receptor activator of nuclear factor κB in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro.
Owen S; Sanders AJ; Mason MD; Jiang WG
Int J Oncol; 2016 Mar; 48(3):919-28. PubMed ID: 26781475
[TBL] [Abstract][Full Text] [Related]
3. Phospholipase-C gamma-1 (PLCgamma-1) is critical in hepatocyte growth factor induced in vitro invasion and migration without affecting the growth of prostate cancer cells.
Davies G; Martin TA; Ye L; Lewis-Russell JM; Mason MD; Jiang WG
Urol Oncol; 2008; 26(4):386-91. PubMed ID: 18367108
[TBL] [Abstract][Full Text] [Related]
4. Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment.
Sobkowicz AD; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2017 Aug; 37(8):4255-4268. PubMed ID: 28739717
[TBL] [Abstract][Full Text] [Related]
5. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
6. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
7. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
8. Expression of the prostate transglutaminase (TGase-4) in prostate cancer cells and its impact on the invasiveness of prostate cancer.
Davies G; Ablin RJ; Mason MD; Jiang WG
J Exp Ther Oncol; 2007; 6(3):257-64. PubMed ID: 17552366
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Fizazi K; Yang J; Peleg S; Sikes CR; Kreimann EL; Daliani D; Olive M; Raymond KA; Janus TJ; Logothetis CJ; Karsenty G; Navone NM
Clin Cancer Res; 2003 Jul; 9(7):2587-97. PubMed ID: 12855635
[TBL] [Abstract][Full Text] [Related]
10. Enhanced invasion of hormone refractory prostate cancer cells through hepatocyte growth factor (HGF) induction of urokinase-type plasminogen activator (u-PA).
Hall CL; Tsan R; Mugnai G; Mazar A; Radinsky R; Pettaway CA
Prostate; 2004 May; 59(2):167-76. PubMed ID: 15042617
[TBL] [Abstract][Full Text] [Related]
11. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells.
Davies G; Watkins G; Mason MD; Jiang WG
Prostate; 2004 Sep; 60(4):317-24. PubMed ID: 15264243
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Ye L; Lewis-Russell JM; Davies G; Sanders AJ; Kynaston H; Jiang WG
Int J Oncol; 2007 Feb; 30(2):521-9. PubMed ID: 17203235
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
14. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
15. Effect of hepatocyte growth factor on invasion of prostate cancer cell lines.
Fujiuchi Y; Nagakawa O; Murakami K; Fuse H; Saiki I
Oncol Rep; 2003; 10(4):1001-6. PubMed ID: 12792760
[TBL] [Abstract][Full Text] [Related]
16. Genetic reduction of matriptase-1 expression is associated with a reduction in the aggressive phenotype of prostate cancer cells in vitro and in vivo.
Sanders AJ; Parr C; Davies G; Martin TA; Lane J; Mason MD; Jiang WG
J Exp Ther Oncol; 2006; 6(1):39-48. PubMed ID: 17228523
[TBL] [Abstract][Full Text] [Related]
17. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
[TBL] [Abstract][Full Text] [Related]
18. HGFK1 inhibits bone metastasis in breast cancer through the TAK1/p38 MAPK signaling pathway.
Yao Y; Fang ZP; Chen H; Yue L; Min DL; Tang LN; Yu WX; Kung HF; Lin MC; Shen Z
Cancer Gene Ther; 2012 Sep; 19(9):601-8. PubMed ID: 22767217
[TBL] [Abstract][Full Text] [Related]
19. Prostate carcinoma cells that have resided in bone have an upregulated IGF-I axis.
Rubin J; Chung LW; Fan X; Zhu L; Murphy TC; Nanes MS; Rosen CJ
Prostate; 2004 Jan; 58(1):41-9. PubMed ID: 14673951
[TBL] [Abstract][Full Text] [Related]
20. Suppression of hepatocyte growth factor activator inhibitor-1 leads to a more aggressive phenotype of prostate cancer cells in vitro.
Sanders AJ; Parr C; Mason MD; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):613-9. PubMed ID: 17786295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]